
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
In a study conducted in the pediatric clinics of a major public urban hospital, investigators documented that 55% of almost 500 children were exposed to second-hand smoke (SHS), even though only 13% of their parents reported such exposure.






